Overall verdict
Buy
6.5/10
1-year performance
+10.31%
Score breakdown
Up 10.3% over 1 year, 46% of the 52-week range.
Strongest: Profitability 9.2/10. Weakest: Growth 3.6/10.
23 analysts, target +0.3% vs the price.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI.
It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia.
It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology ; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications ; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Sector
Health Care
Industry
Pharmaceuticals
Primary listing
Lse
United Kingdom
CEO
Pascal Claude Soriot
Founded
1992
Employees
96 100
Revenue / employee
624 822 USD
Next earnings
October 30, 2026
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
157.32 GBP
52-week low
98.92 GBP
1-year performance
10.31%
Rising
Year-to-date performance
-9.98%
Rising
Drawdown
-20.21%
Marked drawdown
Position in the 52-week range
46% of range
Range: 127.28 GBP - 142.31 GBP (2 methods agree)
The price implies growth of 7.16% per year; the company grows at 21.21%.
Gross margin 73.9%, net margin 17.0%, ROIC 14.3%, ROE 22.1%.
Net margin
17.02%
Exceptional
Sector 9.43%|S&P 12.97%
Gross margin
73.92%
Exceptional
Return on equity (ROE)
22.06%
Exceptional
Sector 6.16%|S&P 16.52%
Return on invested capital (ROIC)
14.27%
Exceptional
Free cash flow margin (FCF)
17.84%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.05x
High
Margin stability
4.8 pts
Steady
Revenue to net income
Growth
3.6/10Revenue up 5.8% over 1 year, 15.7% a year over 5, EPS 21.2% a year over 5.
Revenue (trailing 12 months)
60.6Md USD
Revenue growth (1y)
5.84%
Solid
Revenue growth (3y)
23.79%
Solid
EPS growth (1y)
1.71%
Moderate
EPS CAGR (5y)
21.21%
Exceptional
EPS revisions (3 months)
-0.42%
Revised down
Valuation
6.1/10P/E 25.1x, forward P/E 21.2x, EV/EBITDA 14.2x, PEG 1.18.
P/E (TTM)
25.1x
Fair
Sector 27.5x|S&P 23.0x
Forward P/E
21.2x
Expensive
EV / EBITDA
14.2x
Fair
Sector 16.1x|S&P 14.5x
PEG
1.18
Fair
Sector 1.05|S&P 0.86
Fair value (reverse DCF)
134.80 GBP
Fairly priced
Market cap
255Md USD
Financial strength
7.0/10Cash covers 15.4% of the debt, net debt/EBITDA 1.2x.
Net debt / EBITDA
1.2x
Solid
Gearing (net debt / equity)
54.14%
Solid
Cash
5.0Md USD
Cash / market cap
1.94%
Stretched
Cash / total debt
15.41%
Tight
Interest coverage
6.8x
Solid
Net debt
27.2Md USD
Equity
50.3Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 124.00 GBP
- MM20121.30
- MM50121.87
- MM200135.98
- RSI 1454.6
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-1.19%
200-day average slope, 3 months
-0.45%
50-day average slope, 1 month
-4.97%
Price structure
Lower lows
Bullish RSI divergence
Yes
20-day volatility
1.37 % per day
Volatility change
-23.16%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 7.84 (14) | 10.25 (24) | 63 166 (27) | 22 193 (17) | 12 044 (15) |
| 2027 | 8.99 (15) | 11.45 (24) | 67 011 (27) | 24 358 (19) | 13 773 (16) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 21, 2026.
Same sub-industry: 509 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BMY | 7.2 | 7.8 | 125Md USD | 13.5x | 18.9 % | 5.8 % | 14.3 % | 1.9x | 9.2 % | 37.4 % | ||
| 2 | LLY | 6.7 | 6.0 | 1.1T USD | 39.1x | 33.5 % | 47.7 % | 39.8 % | 1.2x | 1.7 % | 58.4 % | ||
| 3 | NOVO B | 6.6 | 7.4 | 170Md USD | 9.5x | 35.3 % | 2.1 % | 38.9 % | 0.7x | 6.7 % | -32.6 % | ||
| 4 | AZN | 6.5 | 6.7 | 255Md USD | 25.1x | 17.0 % | 5.8 % | 14.3 % | 1.2x | 4.2 % | 10.3 % | ||
| 5 | NOVN | 6.4 | 6.4 | 261Md USD | 22.6x | 23.3 % | -2.0 % | 17.2 % | 1.0x | 6.3 % | 22.0 % | ||
| 6 | JNJ | 6.2 | 5.7 | 649Md USD | 31.2x | 21.5 % | 6.6 % | 17.5 % | 0.9x | 3.4 % | 53.7 % | ||
| 7 | ROP | 6.1 | 5.7 | 352Md USD | 23.7x | 20.3 % | 1.7 % | 21.8 % | 0.8x | 5.2 % | 35.9 % | ||
| 8 | MRK | 5.0 | 4.4 | 365Md USD | 118.4x | 4.8 % | 4.9 % | 3.6 % | 1.2x | 4.4 % | 85.2 % | ||
| 9 | PFE | 4.9 | 4.6 | 161Md USD | 37.3x | 6.8 % | 2.6 % | 3.0 % | 2.3x | 6.8 % | 17.5 % |
